Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma

• Main Authors: Can G. Leineweber (Author), Miriam Rabehl (Author), Anne Pietzner (Author), Nadine Rohwer (Author), Michael Rothe (Author), Maciej Pech (Author), Bruno Sangro (Author), Rohini Sharma (Author), Chris Verslype (Author), Bristi Basu (Author), Christian Sengel (Author), Jens Ricke (Author), Nils Helge Schebb (Author), Karsten-H. Weylandt (Author), Julia Benckert (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Hepatocellular carcinoma (HCC) is a leading cause of cancer death, and medical treatment options are limited. The multikinase inhibitor sorafenib was the first approved drug widely used for systemic therapy in advanced HCC. Sorafenib might affect polyunsaturated fatty acids (PUFA)-derived epoxygenat...